Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Cold Shower For Viagra: How Congress Can Chill A Market

This article was originally published in RPM Report

Executive Summary

Pfizer, Lilly and the other marketers of drugs for erectile dysfunction are kicked out of Medicare and Medicaid. Viagra and the other brands may be the first victims of the backlash against DTC advertising. They are also a case study in how Congress can--and well--make mischief under the Medicare program.

You may also be interested in...



Second-Guessing FDA: CMS' Expanding Regulatory Role

Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.

Second-Guessing FDA: CMS' Expanding Regulatory Role

Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.

Health Care Reform and Business Development: 10 Reasons it Matters

The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel